Ratings by Citizens (Roy Buchanan)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/1/2025 | PolyPid Ltd. | PYPD | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 11/4/2025 | Inovio Pharmaceuticals | INO | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 10/22/2025 | Dynavax Technologies | DVAX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 10/21/2025 | Cidara Therapeutics | CDTX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 10/3/2025 | Cidara Therapeutics | CDTX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 9/24/2025 | Assembly Biosciences | ASMB | New Coverage | Market Outperform (N/A) |
24.78 (24.57) |
-0.85% | Details | |
| 8/22/2025 | Dynavax Technologies | DVAX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 8/19/2025 | Cidara Therapeutics | CDTX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/13/2025 | Inovio Pharmaceuticals | INO | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 8/12/2025 | Enanta Pharmaceuticals | ENTA | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 8/8/2025 | Dynavax Technologies | DVAX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 8/8/2025 | Cidara Therapeutics | CDTX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 6/30/2025 | Cidara Therapeutics | CDTX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 6/23/2025 | Dynavax Technologies | DVAX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 6/17/2025 | PolyPid Ltd. | PYPD | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 6/12/2025 | CureVac | CVAC | Downgrade | Market Perform (Market Outperform) |
4.07 (4.66) |
14.5% | Details | |
| 6/5/2025 | Cidara Therapeutics | CDTX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 6/3/2025 | Enanta Pharmaceuticals | ENTA | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 6/2/2025 | Cidara Therapeutics | CDTX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 5/28/2025 | CureVac | CVAC | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 5/27/2025 | Cidara Therapeutics | CDTX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 5/14/2025 | Inovio Pharmaceuticals | INO | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 5/14/2025 | Enanta Pharmaceuticals | ENTA | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 5/9/2025 | Cidara Therapeutics | CDTX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 5/7/2025 | Dynavax Technologies | DVAX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 5/5/2025 | AN2 Therapeutics | ANTX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 4/29/2025 | Cidara Therapeutics | CDTX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 3/31/2025 | Arbutus Biopharma | ABUS | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 3/26/2025 | AN2 Therapeutics | ANTX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 3/26/2025 | AN2 Therapeutics | ANTX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 3/19/2025 | Inovio Pharmaceuticals | INO | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 3/14/2025 | Inovio Pharmaceuticals | INO | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 3/12/2025 | Cidara Therapeutics | CDTX | New Coverage | Market Outperform (N/A) |
22.39 (221.38) |
888.74% | Details | |
| 2/25/2025 | AN2 Therapeutics | ANTX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/21/2025 | Dynavax Technologies | DVAX | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/20/2025 | AN2 Therapeutics | ANTX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/11/2025 | Enanta Pharmaceuticals | ENTA | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/3/2025 | AN2 Therapeutics | ANTX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 1/28/2025 | AN2 Therapeutics | ANTX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 11/26/2024 | Enanta Pharmaceuticals | ENTA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/21/2024 | HOOKIPA Pharma Inc. | HOOK | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/9/2024 | Enanta Pharmaceuticals | ENTA | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 10/1/2024 | Gritstone bio | GRTS | Downgrade | Market Perform (Market Outperform) |
0.61 (0.03) |
-95.08% | Details | |
| 9/12/2024 | AN2 Therapeutics | ANTX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/19/2024 | Gritstone bio | GRTS | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/16/2024 | CureVac | CVAC | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/9/2024 | HOOKIPA Pharma Inc. | HOOK | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/9/2024 | AN2 Therapeutics | ANTX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/2/2024 | Arbutus Biopharma | ABUS | Maintain | Market Outperform (N/A) |
|
Details | ||
| 7/26/2024 | HOOKIPA Pharma Inc. | HOOK | Maintain | Market Outperform (N/A) |
|
Details | ||
| 5/7/2024 | Enanta Pharmaceuticals | ENTA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 4/2/2024 | Gritstone bio | GRTS | Maintain | Market Outperform (N/A) |
|
Details | ||
| 4/2/2024 | AN2 Therapeutics | ANTX | Upgrade | Market Outperform (Market Perform) |
3.25 (4.20) |
29.23% | Details | |
| 2/28/2024 | Gritstone bio | GRTS | New Coverage | Market Outperform (N/A) |
2.45 (0.61) |
-75.1% | Details | |
| 2/12/2024 | AN2 Therapeutics | ANTX | Downgrade | Market Perform (Market Outperform) |
20.00 (4.20) |
-79% | Details | |
| 1/29/2024 | HOOKIPA Pharma Inc. | HOOK | Maintain | Market Outperform (N/A) |
|
Details | ||
| 1/4/2024 | Inovio Pharmaceuticals | INO | New Coverage | Market Outperform (N/A) |
0.56 (1.14) |
103.57% | Details | |
| 1/4/2024 | AN2 Therapeutics | ANTX | New Coverage | Market Outperform (N/A) |
19.87 (4.20) |
-78.86% | Details | |
| 11/21/2023 | Enanta Pharmaceuticals | ENTA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/12/2023 | Arbutus Biopharma | ABUS | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/8/2023 | Enanta Pharmaceuticals | ENTA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/4/2023 | Dynavax Technologies | DVAX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 7/18/2023 | Pardes Biosciences | PRDS | Downgrade | Market Perform (Market Outperform) |
1.85 (2.16) |
16.76% | Details | |
| 5/9/2023 | Enanta Pharmaceuticals | ENTA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 5/3/2023 | Dynavax Technologies | DVAX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 4/26/2023 | CureVac | CVAC | Maintain | Market Outperform (N/A) |
|
Details | ||
| 2/24/2023 | Dynavax Technologies | DVAX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 2/15/2023 | iBio, Inc. | IBIO | Downgrade | Market Perform (Market Outperform) |
0.88 (1.84) |
109.09% | Details | |
| 1/23/2023 | CureVac | CVAC | Maintain | Market Outperform (N/A) |
|
Details | ||
| 12/13/2022 | Pardes Biosciences | PRDS | New Coverage | Market Outperform (N/A) |
1.20 (2.16) |
80% | Details | |
| 11/17/2022 | CureVac | CVAC | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/27/2022 | Dynavax Technologies | DVAX | New Coverage | Market Outperform (N/A) |
10.24 (15.50) |
51.37% | Details | |
| 8/9/2022 | Enanta Pharmaceuticals | ENTA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/3/2022 | PolyPid Ltd. | PYPD | Maintain | Market Outperform (N/A) |
|
Details | ||
| 6/28/2022 | Arbutus Biopharma | ABUS | Maintain | Market Outperform (N/A) |
|
Details | ||
| 5/19/2022 | Enanta Pharmaceuticals | ENTA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 5/10/2022 | Enanta Pharmaceuticals | ENTA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 4/22/2022 | CureVac | CVAC | Maintain | Market Outperform (N/A) |
|
Details | ||
| 1/18/2022 | CureVac | CVAC | New Coverage | Market Outperform (N/A) |
24.48 (4.66) |
-80.96% | Details | |
| 12/13/2021 | Arbutus Biopharma | ABUS | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/29/2021 | iBio, Inc. | IBIO | New Coverage | Market Outperform (N/A) |
0.67 (1.84) |
174.63% | Details | |
| 11/23/2021 | Enanta Pharmaceuticals | ENTA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/10/2021 | PolyPid Ltd. | PYPD | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/10/2021 | HOOKIPA Pharma Inc. | HOOK | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/8/2021 | Enanta Pharmaceuticals | ENTA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/8/2021 | Arbutus Biopharma | ABUS | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/5/2021 | Arbutus Biopharma | ABUS | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/20/2021 | Enanta Pharmaceuticals | ENTA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/4/2021 | Enanta Pharmaceuticals | ENTA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/14/2021 | PolyPid Ltd. | PYPD | New Coverage | Market Outperform (N/A) |
8.07 (4.72) |
-41.51% | Details | |
| 5/7/2021 | Enanta Pharmaceuticals | ENTA | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 4/30/2021 | Enanta Pharmaceuticals | ENTA | Maintain | Market Outperform (N/A) |
|
Details |
